Regional thalamic neuropathology in patients with hippocampal sclerosis and epilepsy: A postmortem study by Sinjab, B et al.
Regional thalamic neuropathology in patients with
hippocampal sclerosis and epilepsy: A postmortem study
*Barah Sinjab, *LillianMartinian, *†‡SanjayM. Sisodiya, and *§Maria Thom
Epilepsia, 54(12):2125–2133, 2013
doi: 10.1111/epi.12403
SUMMARY
Purpose: Clinical, experimental, and neuroimaging data all indicate that the thalamus is involved in the network of
changes associated with temporal lobe epilepsy (TLE), particularly in association with hippocampal sclerosis (HS), with
potential roles in seizure initiation and propagation. Pathologic changes in the thalamus may be a result of an initial
insult, ongoing seizures, or retrograde degeneration through reciprocal connections between thalamic and limbic
regions. Our aim was to carry out a neuropathologic analysis of the thalamus in a postmortem (PM) epilepsy series, to
assess the distribution, severity, and nature of pathologic changes and its association with HS.
Methods: Twenty-four epilepsy PM cases (age range 25–87 years) and eight controls (age range 38–85 years) were stud-
ied. HS was classified as unilateral (UHS, 11 cases), bilateral (BHS, 4 cases) or absent (No-HS, 9 cases). Samples from
the left and right sides of the thalamus were stained with cresyl violet (CV), and for glial firbillary acidic protein (GFAP)
and synaptophysin. Using image analysis, neuronal densities (NDs) or field fraction staining values (GFAP, synaptophy-
sin) were measured in four thalamic nuclei: anteroventral nucleus (AV), lateral dorsal nucleus (LD), mediodorsal
nucleus (MD), and ventrolateral nucleus (VL). The results were compared within and between cases.
Key Findings: The severity, nature, and distribution of thalamic pathology varied between cases. A pattern that
emerged was a preferential involvement of the MD in UHS cases with a reduction in mean ND ipsilateral to the side of
HS (p = 0.05). In UHS cases, greater field fraction values for GFAP and lower values for synaptophysin and ND were
seen in themajority of cases in theMD ipsilateral to the side of sclerosis compared to other thalamic nuclei. In addition,
differences in the mean ND between classical HS, atypical HS, and No-HS cases were noted in the ipsilateral MD
(p < 0.05), with lower values observed inHS.
Significance: Our study demonstrates that stereotypical pathologic changes, as seen in HS, are not clearly defined in
the thalamus. This may be partly explained by the heterogeneity of our PM study group. With quantitation, there is
some evidence for preferential involvement of the MD, suggesting a potential role in TLE, which requires further inves-
tigation.
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Sclerosis of the hippocampus is one of the most common
and best characterized pathologies identified at both post-
mortem (Margerison & Corsellis, 1966; Meencke et al.,
1996) and in surgical series of patients with epilepsy, and is
particularly associated with the syndrome of mesial
temporal lobe epilepsy (MTLE; Blumcke, 2009). In surgical
series, hippocampal sclerosis (HS) is typically encountered
in specimens from young adults, in the context of refractory
seizures, with sclerosis visible on magnetic resonance imag-
ing (MRI) and confirmed in resected specimens (Wieser,
2004). Neuropathology studies have, from the outset, recog-
nized that more extensive, albeit more subtle, pathology
may accompany HS (Cavanagh & Meyer, 1956). In recent
years, clinical and neuroimaging studies have also moved
away from a “hippocampocentric” view of MTLE (Thom
et al., 2010a; Engel & Thompson, 2012). The additional
structures altered include those anatomically linked to, or in
proximity of, the hippocampus, such as the amygdala
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(Bernasconi et al., 2003), entorhinal cortex (Bernasconi
et al., 1999; Jutila et al., 2001; Bernasconi et al., 2003;
Bonilha et al., 2004; Keller et al., 2004), temporal pole
(Coste et al., 2002; Sankar et al., 2008), and cingulate gyrus
(Bernhardt et al., 2008; Bonilha et al., 2010a). This wider
network of disease may correlate with an extended zone of
epileptogenesis and explain poor outcomes in some patients
following focal surgery, as well as offer an explanation for
comorbidities associated with HS as progressive memory
decline.
Neuropathologic study of the thalamus is merited in
patients with HS for several reasons. The hippocampus has
important reciprocal connections to the thalamus (Hirai &
Jones, 1989; Herrero et al., 2002). The main output pathway
of the hippocampus (fornix) projects through the medial
mamillary nucleus to the anteroventral thalamic nucleus
(AV); the anterior and lateral dorsal thalamic nuclei are both
reciprocally connected with the limbic cortex; the medio-
dorsal nucleus (MD) also receives input from the amygdala,
entorhinal cortex, and temporal pole (Nieuwenhuys et al.,
2008a). A number of experimental studies have indicated
that the thalamus plays a crucial role in seizure initiation
and modulation, thereby strongly suggesting that it may be
an important part of the substrate for MTLE (Bertram et al.,
2008; Sloan & Bertram, 2009; Sloan et al., 2011). In addi-
tion, there are data from electroclinical studies supporting
synchronization of activity in the thalamus in association
with temporal lobe seizures (Guye et al., 2006). The neuroi-
maging literature also points toward volume loss occurring
in the thalamus in TLE, although there are inconsistencies
between studies regarding its association with HS, whether
greater volume loss is observed ipsilateral to side of HS, as
well as the regional distribution of pathology within the
thalamus (DeCarli et al., 1998; Dreifuss et al., 2001; Beh-
rens et al., 2003; Natsume et al., 2003; Bonilha et al., 2004;
Labate et al., 2008; Kim et al., 2010; Mueller et al., 2010;
Alhusaini et al., 2012).
Detailed histologic studies of the thalamus in TLE are
lacking. Neuronal loss has been demonstrated in experimen-
tal models (Bertram & Scott, 2000; Bertram et al., 2001). In
a single postmortem study from 1966, thalamic damage was
frequent in a series of patients with TLE and HS (Margeri-
son & Corsellis, 1966), but not further detailed. Our aim
was to investigate the extent and regional distribution of tha-
lamic pathology in a postmortem epilepsy series using
quantitative immunohistochemistry.
Methods
Case and tissue selection
Postmortem cases were selected from the archives of the
Division of Neuropathology at the National Hospital for
Neurology and Neurosurgery, Queen Square, London. The
local ethics committee of the National Hospital for Neurol-
ogy and Neurosurgery and the Institute of Neurology has
given approval for neuropathologic epilepsy studies, and era-
appropriate consent was obtained from patients’ next-of-kin.
Twenty-four epilepsy cases (age range 25–87; mean age
56.5 years) were selected together with eight controls (age
range 38–85; mean age 59.8 years) without significant neu-
rologic disease or epilepsy (Table S1). The majority of
patients had lifelong, drug-resistant epilepsy. Details of epi-
lepsy history, seizure type, and epilepsy syndrome as well
as recent seizure control are recorded in Table S1. The
patients for this study were selected according to the pres-
ence (or not) of neuropathologically confirmed HS. The
diagnosis of HS was based on previous criteria (Thom et al.,
2005, 2009), and the pattern was defined as classical HS
(CHS: neuronal loss and gliosis in CA1 and CA4) or atypi-
cal HS either CA1 predominant sclerosis (CA1p: neuronal
loss in CA1) or end folium sclerosis (EFS: neuronal loss in
CA4) (Thom et al., 2010b); this equates with HS Interna-
tional League Against Epilepsy (ILAE) types 1, 2, and 3,
respectively, in the new classification (Blumcke et al.,
2013). Cases where only end floium gliosis (EFG) was pres-
ent but with no neuronal loss were considered as No-HS. HS
was classified as unilateral HS (UHS; 11 cases), bilateral
HS (BHS; 4 cases) or No-HS (9 cases) (see Table S1).
The coronal level represented in the sections of thalamus
varied from the subthalamic nucleus to the lateral dorsal tha-
lamic nucleus. In 18 cases thalamic nuclei were sampled at
the time of the postmortem examination, and formalin-fixed
paraffin-embedded, paired tissue blocks from both left and
right sides of thalamus at the same coronal level were avail-
able. In six cases, paired tissue blocks of left and right thala-
mus were sampled from the remaining formalin-fixed brain
tissue. In some cases more than one coronal level was
included through the thalamus to maximize the sampling of
the subnuclei. In the six cases that were re-sampled, fixation
times varied from 3 to 15 years (mean 8.6 years) compared
to 2 to 8 weeks fixation times in the other 18 epilepsy cases.
In one case (EP295-UHS), only one brain hemisphere was
available for examination. We excluded epilepsy cases with
second pathologies involving the thalamus although evi-
dence of old trauma or cerebrovascular injury elsewhere in
the brain was present in some cases (Table 1); all the
patients in the series had low Braak stage for Alzheimer’s
disease. Controls were selected from our own archives and
from the Queen Square Brain Bank. For all control cases bar
one, only one hemisphere (and thalamus) was available for
examination. In all cases a reference hematoxylin and eosin
(H&E) and/or LFB/CV (Luxol fast blue/cresyl violet)–
stained section was available for confirmation and delinea-
tion of the anatomical boundaries of thalamic subnuclei
(Hirai & Jones, 1989).
Tissue preparation
For each case, 7-lm–thick formalin fixed paraffin embed-
ded sections from the left and right side of thalamus were
dewaxed, rehydrated through graded alcohols and immersed
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in distilled water. CV stain was carried out on one section.
Immunohistochemistry for glial fibrillary acidic protein
(GFAP) and synaptophysin were carried out as follows.
Endogenous peroxidase was quenched with 3% hydrogen
peroxide in water. After relevant antigen treatments, sec-
tions were stained for 1 hour at room temperature with the
following antibodies: polyclonal GFAP (1:1,500; Dako,
Glostrup, Denmark) with proteinase K for enzyme diges-
tion, synaptophysin (1:100, Dako) with ethylenediaminete-
traacetic acid (EDTA) heat-mediated epitope retrieval. In
cases with longer fixation times, synaptophysin staining was
not included due to the known diminished labeling over time
with this antibody (Liu et al., 2010). Labeling was detected
with horseradish peroxidase kit (Dako Envision) and diami-
nobenzidine (DAB) for visu- alization. Sections were count-
erstained with hematoxylin.
Quantitative analysis of stained sections
A commercial image analysis system (Histometrix;
Kinetic Imaging, Liverpool, United Kingdom) with a Zeiss
Axioskop (Cambridge, United Kingdom) microscope was
used for the field fraction analysis and for estimation of neu-
ronal number. On the GFAP, synaptophysin, and CV sec-
tions, regions of interest (ROIs) were outlined with
reference to the LFB/CV–stained section for delineation of
the thalamic subnuclei based on the regional cytoarchitec-
ture (Hirai & Jones, 1989; Nieuwenhuys et al., 2008b). Four
different thalamic nuclei were selected for inclusion,
because of their known connections with the hippocampus,
previous literature implicating a role in epilepsy, or the effi-
cacy of their identification in tissue sections. They included
the anteroventral nucleus (AV), lateral dorsal nucleus (LD),
mediodorsal nucleus (MD) and the ventrolateral nucleus
(VL). The entire area of each nucleus was outlined on the
image analyzer program at92.5 magnification (Fig. 1). We
aimed to include the maximal anatomic extent of each sub-
nucleus, but with care to exclude peripheral myelinated
fiber tracts, such as the internal and external medullary lam-
ina. We did not further subdivide the nuclei into their com-
ponents, for example, the magnocellular, parvocellular, and
paralaminar divisions of the MD, but included the entire
area available of each nucleus.
Field fraction analysis was carried out for GFAP- and
synaptophysin-immunostained sections (Blanc et al., 2011)
by calculating the percentage of pixels stained in a given
field at 940. The RGB (red-green-blue) detection threshold
was set for the first field to detect the majority of immuno-
staining, but minimizing nonspecific detection (Fig. 1C,D).
Uniform random sampling of fields examined at high mag-
nification within each ROI was then carried out. In a pilot
study, a sampling fraction of 10% for GFAP, 15% for syn-
aptophysin for the VL and MD nuclei, and 100% sampling
for the AV and LD nuclei was found to give reproducible
measurements upon resampling, with and an average coeffi-
cient of error <0.1. Light intensity and the image analysis
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RGB detection thresholds were kept constant throughout
the entire experiment for each case. Estimates of the per-
centage of GFAP-positive staining averaged over all fields
for each of the four nuclei were calculated. For estimates of
neuronal density on CV-stained sections, similar ROI were
drawn and all cells with a neuronal morphology were
counted at940; a sampling fraction of 15%was selected for
the VL and MD and 100% in the LD and AV for optimal
reproducibility of measurements.
Statistical analysis was carried out using SPSS (IBM)
version 16 and the Mann-Whitney test, Kruskal-Wallis, and
nonparametric correlations (Spearman’s or Kendall’s tests)
for comparison of data between patient groups (p < 0.05
taken as significant).
Results
Regional thalamic subnuclear pathology
We identified the MD and VL (subnuclei) in 92% of
hemispheres and the AV and LD in 42%; in all cases except
two, we were able to define at least three thalamic subnuclei
per section (Fig. 1A). The thalamic structures showed a var-
iable, patchy gliosis throughout the thalamus, more often in
a perivascular distribution (Fig. 1G–I). In no epilepsy cases,
with CV, synaptophysin, or GFAP did we identify distinct
atrophy or sclerosis of a nucleus comparable to the degree
of hippocampal damage in CHS. Quantitative analysis of all
cases and controls, in each of the four subnuclei, did not
show a significant correlation between GFAP, neuronal
A B
C
D
E
F
G I
JH
K
L
Figure 1.
(A) Luxol/fast blue preparation from the thalamus at the level of the subthalamic nucleus highlighted the white matter pathways including
the internal medullary laminae and (B) synaptophysin-stained preparation of the same case with three of the four subnuclei quantified
indicated (MD, mediodorsal nucleus; VL, ventrolateral; AV, anteroventral). (C) Synaptophysin labeling within the VL at940 objective and
(D) the same image with a green overlay used to detect the field fraction of immunostaining with the image analyzer. (E, F) In one of the
controls with GFAP staining, an even distribution of positively labeled astrocytes and processes were observed in the VL (E) and MD (F).
Similarly in a patient with No-HS and Dravet syndrome there was no qualitative variability between GFAP staining in the VL (G) and MD
(H) or between the left and right sides (as labeled), which was confirmed with quantitative values. In a patient with TLE and unlilateral left-
sided CHS shown in (I, J) there was no difference between the level of staining in the left or right VL subnuclei (values of 12.5% and 11%
field fraction staining at940). Higher field fractions were noted in the MD (J) but were not different between the left (16%) and right sides
(17.4%). (K, L) In a patient with bilateral CHS, there appeared slightly greater, but symmetrical increase in GFAP in the VL compared to
the unilateral CHS (13.1% and 14.7%, left and right, respectively) in addition to a symmetrically greater increase in gliosis in the MD
(19.9% and 19.8%, left and right, respectively). Bar = 100 l for (E–L).
Epilepsia ILAE
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density, and synaptophysin measurements (Fig. 1C,D),
apart from the LD, which showed a positive correlation
between CV and synaptophysin (p < 0.05). In the control
group, regarding regional variation in synaptophysin stain-
ing, higher mean field fractions were present in the AV than
the MD (Table 1, p < 0.001) supporting a normal variation
in synaptic density; there was, however, no significant dif-
ference in the variation of mean neuronal density on CV
stain or astrocytic gliosis between subnuclei in controls.
Comparison of all pathology measures between the epilepsy
groups (UHS, BHS, and No-HS) and controls showed sig-
nificant differences for neuronal density in the VL, MD, and
LD (p < 0.01, p < 0.05 and p < 0.05; Table 1), with higher
values noted in the patients with epilepsy.
Comparison of left and right thalamic nuclei in
unilateral HS group
We analyzed the patterns within patient subgroups. In the
11 UHS cases, there was a trend for significant reduction in
the neuronal density in the MD ipsilateral to the side of HS
compared to the contralateral side (p = 0.05). No signifi-
cant differences were noted in other subnuclei, either with
GFAP or synaptophysin staining. Furthermore, no signifi-
cant differences were noted for similar comparisons in the
BHS and No-HS epilepsy groups.
Direct comparison of measurement values between left
and right sides within individual cases avoids any variability
of staining intensity due to differences in tissue-fixation
times and processing. Although no consistent patterns were
seen, in UHS cases, greater values with GFAP and lower
values with synaptophysin and neuronal density were seen
for the majority of cases in the MD ipsilateral to the side of
sclerosis (Fig. 2A) compared to other thalamic nuclei, sug-
gesting more frequent pathology (neuronal loss, synaptic
reduction, or gliosis) in this subnucleus. Furthermore, by
expressing the measurements in each subnucleus on the
sclerotic side as a ratio of the contralateral side, the lowest
values for CV and synaptophysin (reflecting the greatest
pathologic changes) were confirmed for the MD (Fig. 2B).
However, when a similar analysis was carried out for the
nine No-HS epilepsy cases, compared with the UHS cases,
there was no statistically significant difference in these
ratios (Fig. 2B). There was also no significant difference in
these ratios in the UHS group regardless of whether the scle-
rosis was on the left or right side.
Comparison of thalamic nuclei in relation to pattern of
HS
Comparing CHS (ILAE type 1), atypical HS patterns
(ILAE types 2 and 3), and No-HS epilepsy patients,
lower values for synaptophysin labeling were noted ipsi-
lateral to CHS in all thalamic nuclei, although these dif-
ferences were not significant. There was a statistically
significant difference between the mean ND on CV in
the VL between these groups (p < 0.05) and a trend for
a difference in GFAP in the MD (p = 0.08); both values
were lowest in atypical HS.
Comparison in relation to clinical and pathology feature
Clinicopathologic correlations showed an association of
reduced synaptophysin labeling in the VL (subnucleus) in
patients with TLE (p < 0.05) and lower neuronal density on
CV in the AV in both TLE and partial epilepsy syndromes
compared to other epilepsy cases (p < 0.01). Because most
patients had generalized seizures in addition to partial sei-
zures in this small group, it was not possible to assess tha-
lamic damage in relation to seizure type. There was a
negative correlation between the age of death and synapto-
physin field fractions in the AV (p = 0.018). The mean age
of onset of epilepsy was 8 years (range 0.3–28 years) and
the mean duration of epilepsy (age of onset of habitual sei-
zures until most recent seizure) was 45 years (range 2–86
years); there was a positive correlation between duration of
epilepsy and the field fraction of GFAP in the VL
(p < 0.05) and the AV (p < 0.05). There were no significant
differences in any of the pathology measures in relation to
whether the patient had refractory epilepsy or was in remis-
sion at the time of death. There were no significant correla-
tions between the presence of cognitive decline, brain
weight, the presence of traumatic brain injury, or cerebro-
vascular disease (CVD) and any of the measures in the tha-
lamic nuclei. There were no significant differences in
GFAP measures and CV neuronal density between cases
that had short or long fixations. The synaptophysin was not
assessed in long fixation cases, so statistical analysis was
not carried out.
Discussion
There is converging clinical, experimental, and neuroi-
maging evidence that hippocampal sclerosis in epilepsy
may represent part of a wider network of pathologic
changes, including within the thalamus. In this first detailed
neuropathologic study of the thalamus in epilepsy, we have
demonstrated that, in contrast to the stereotypical patterns
of sclerosis (neuronal loss and gliosis) observed in the hip-
pocampus, cellular alterations within subthalamic nuclei
are milder, less clearly defined, varying both in regional
distribution, nature, as well as severity. It remains to be
established whether any of the extended regional patholo-
gies accompanying HS are as a result of the same initial
“insult,” represent secondary progressive changes, such as
retrograde/anterograde degeneration along known projec-
tions, or arise independently as a result of the seizures.
Indeed all of these mechanisms may operate. We employed
three standard neuropathologic measurements in this initial
assessment of the thalamus to quantify total synaptic den-
sity as a measure of connectivity (synaptophysin), neuronal
number (cresyl violet), and gliosis (GFAP) in selected sub-
nuclei. These measurements did not correlate with each
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other (except for the LD nucleus), suggesting that the path-
ologic processes of astrocytic gliosis and alterations in
synaptic and neuronal density may not occur synchronously.
We did not demonstrate significant differences between
all the patients with epilepsy compared to controls. Indeed
for some subnuclei, higher neuronal densities were noted in
epilepsy groups than in controls. A possible explanation for
this is that gliosis (and therefore tissue volume reduction)
may predominate over neuronal loss, resulting in a paradoxi-
cal increase in cell density (cell number per area). When con-
sidered as groups, based on the presence or not of HS, some
patterns did emerge. Several observations pointed to regional
pathology preferentially involving the MD in UHS, with evi-
dence of lateralization to the side of sclerosis. We demon-
strated significantly lower mean neuronal density ipsilateral
to side of sclerosis in UHS cases in the MD compared to the
contralateral side. Within individual HS cases, greater GFAP,
lower synaptophysin and neuronal density between sides
were more consistently seen in the MD than other nuclei,
lateralizing to the side of sclerosis. Such comparisons within
individual cases may prove a more reliable measurement
than comparison between postmortem groups, as technical
variations in staining dependent on tissue quality and fixation
times are circumvented; in addition, the anatomic coronal
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Figure 2.
Comparison between left and right hemispheres in unilateral HS group. (A). The value for each measurement in each case in the thalamic
subnuclei on the side ipsilateral to the side of CHS was compared to the contralateral side and value ranked as either higher or lower.
The DM showed lateralization to the side of sclerosis in the majority of cases with all markers (B) Ratio of interhemispheric values
between nuclei in epilepsy groups with unilateral hippocampal sclerosis (UHS) or without sclerosis (No-HS). In UHS cases this ratio is
expressed as side ipsilateral to HS: contralateral side; in No-HS the ratio is left: right side. A ratio near to 1 implies little difference
between the left and the right hemisphere. The mean values of the ratios in each group and the standard deviations are shown as bars.
Although the lowest values for CV and synaptophysin were seen in the MD in UHS group, there were no statistically significant differences
overall between UHS and No-HS groups. Furthermore, in the UHS cases there was no significant difference in ratios in regard to laterality
of the sclerosis. VL, ventrolateral thalamic nucleus; MD, mediodorsal nucleus; AV, anteroventral nucleus; LD, lateral dorsal nucleus; syn,
synaptophysin; CV, cresyl violet; ND, neuronal density; CHS, classical hippocampal sclerosis.
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level through thalamic subnuclei are more exactly matched
when sampling tissue blocks. These findings could support
the notion that pathology in the MD is more consistently
present in HS associated with epilepsy.
The MD receives incoming networks from the amygdala,
entorhinal cortex, and temporal pole (Nieuwenhuys et al.,
2008a) and is connected to the prefrontal cortex; it has phys-
iologic roles in cognition and working memory (Watanabe
& Funahashi, 2012). There is experimental evidence sup-
porting a role for the MD in epilepsy.
Cassidy and Gale reported that pretreatment of the MD
with inhibitory agents protected against the development of
seizures (Cassidy & Gale, 1998). Bertram also demon-
strated seizure activity within the midline thalamus occur-
ring simultaneously with the onset of seizures evoked by
hippocampal stimulation in rats (Bertram et al., 2001), as
well as induction of hippocampal seizures through stimula-
tion of the MD (Bertram et al., 2008). This was found to be
specific to the MD, implicating this thalamic region in the
initial stages of limbic seizures. Furthermore, the seizures
stimulated from MD were found to quickly generalize to
surrounding areas, supporting a role for the MD in seizure
spread (Bertram et al., 2008). Histologic studies in experi-
mental models of MTLE have also demonstrated significant
neuronal loss in the MD compared to controls (Bertram
et al., 2001). In surgical series of patients with TLE, exami-
nation of the thalamus is clearly not possible and human his-
tologic studies are dependent on postmortem series. In the
only previous postmortem study by Margerison & Corsellis
(1966) in 55 patients with TLE, thalamic “scarring” was
seen in 25% of cases, more often in association with HS. In
this study, they noted that the severity and distribution of
damage varied, but with no predilection for a particular
nuclear group. However, in their study, quantitative immu-
nohistochemistry was not carried out as in the present study,
which may have the power to detect and evaluate more
subtle pathology.
Stereoelectroencephalography studies in human TLE
have shown synchrony between the thalamus and cortex in
patients with TLE (Guye et al., 2006); it has been suggested
that the thalamus could act as a seizure amplifier and syn-
chronizer of ictal activity (Guye et al., 2006). Magnetic res-
onance imaging (MRI) studies have greatly advanced our
understanding of associated alterations of the thalamus in
TLE. Using manual segmentation methods (Moran et al.,
2001; Natsume et al., 2003), voxel based morphometry
(VBM) (Bonilha et al., 2004), and diffusion tensor imaging
(DTI) (Kim et al., 2010) volume reductions in the thalamus
have been shown ipsilateral to the side of seizure onset
(DeCarli et al., 1998; Dreifuss et al., 2001; Moran et al.,
2001; Natsume et al., 2003; Bonilha et al., 2004; Kim
et al., 2010; Mueller et al., 2010; Bonilha et al., 2010b; Al-
husaini et al., 2012) associated both with (Alhusaini et al.,
2012; Kim et al., 2010; Mueller et al., 2010) and without
HS (Natsume et al., 2003). Some MR studies support
greater involvement of the anterior thalamus (Bonilha et al.,
2005; Mueller et al., 2010), and there are contradictory
studies suggesting relative differences in the extent of con-
tralateral thalamic atrophy associated with right- versus
left-sided HS (Morgan et al., 2012; Pail et al., 2010). We
failed to detect any differences in the lateralization of tha-
lamic pathology between right- or left-sided CHS cases. A
more recent MRI study, has mapped and localized thalamic
atrophy to the ipsilateral medial thalamic surface (Bernhardt
et al., 2012), which is comparable to our identification of
pathology preferentially localizing to the MD nucleus. Posi-
tron emission tomography (PET) studies have also localized
hypometabolism in the ipsilateral MD subnuclei in patients
with TLE (Juhasz et al., 1999).
Clinical and imaging studies have also been evaluated in
an attempt to gain further insight of the cause and progres-
sion of thalamic pathology. Natsume showed a negative cor-
relation between thalamic volume and duration of TLE in
40 patients with TLE (Natsume et al., 2003). Duration of
epilepsy was also shown to correlate with progressive tha-
lamic changes observed in patients with HS using DTI (Kel-
ler et al., 2012). Not all studies, however, have shown a
relationship between loss of thalamic volume and duration
of epilepsy (Alhusaini et al., 2012). The question of pro-
gressive changes becomes more difficult to address in post-
mortem tissues from patients mainly at the end-stage of
disease, but we did identify an association between the
extent of gliosis in the VL and AV and total duration of epi-
lepsy. A similar association was not seen for age at death,
suggesting that this may represent a seizure-related effect.
A further proposal, that thalamic pathology represents
transsynaptic degeneration following secondary deafferen-
tation in hippocampal networks, was supported in one
recent study combining volumetric MRI study with tractog-
raphy, suggesting a relationship between alterations
observed with these methods (Bonilha et al., 2010b). The
evidence for loss of thalamic volume associated with HS in
patients with mild (drug-sensitive) TLE (Labate et al.,
2008) also supports this hypothesis of atrophy secondary to
degeneration in the network rather than a direct seizure
effect. As the main output pathway of the hippocampus, via
the fornix and medial mamillary nucleus, is to the AV, we
might anticipate greater atrophy in this nucleus. Indeed,
stimulation of the AV has recently been trialed as an effec-
tive treatment in refractory epilepsy of temporal origin
(Fisher et al., 2010), with these direct connections between
the anterior nucleus and the hippocampus implicated in this
therapeutic effect (Fridley et al., 2012). However, in our
small series we failed to confirm significant pathology pref-
erentially involving the AV, either in single cases or in
groups of HS cases. Finally, MRI studies have shown smal-
ler thalamic volumes with a history of febrile seizures as a
potential precipitating insult for thalamic pathology
(Natsume et al., 2003); it was not possible to investigate the
contribution of initial injury to thalamic pathology in the
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present clinical series because of the lack of sufficient early
historic data in many cases.
There are several limitations in the present study. One of
the main ones being that this postmortem group represents a
more heterogenous cohort than surgical epilepsy series, par-
ticularly in terms of the epilepsy syndrome in that not all
patients have MTLE, which may partly explain the lack of
consistent thalamic pathology observed. Tissue processing
and differences in fixation times can influence the intensity
of immunostaining.We attempted to overcome this problem
by comparing the left and right sides within individual cases
in addition to mean values between groups. Although we
aimed to exclude confounding pathologies, we cannot
exclude, particularly in older patients, the contribution of
subclinical cerebrovascular disease to thalamic gliosis and
neuronal loss. Not all thalamic subnuclei were represented
in each case, and the thalamic coronal levels at which sub-
nuclei were sampled, varied between cases, which could
influence data. In addition, we did not subdivide the nuclei
further, which may reduce the sensitivity of detecting focal
pathology. A further prospective PM study with sampling
through the entire thalamus, utilizing three-dimensional
stereologic analysis, may be required to further study the
MD in detail.
In summary, our PM study demonstrates that stereotypi-
cal pathologic changes, as seen in HS, are not consistently
or clearly defined in the thalamus. We did identify a predi-
lection for neuronal and synaptic loss and gliosis in the MD,
in keeping with previous clinical and experimental data,
supporting the potential role of the MD in epilepsy. This is
an area that warrants further detailed investigation.
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